Gout
SGLT2 inhibitors ‘substantially’ reduce gout risk in patients with type 2 diabetes
SAN DIEGO — Sodium-glucose cotransporter-2 inhibition may reduce the risk for gout by as much as 40% to 60% among certain patients with type 2 diabetes treated with metformin, according to data presented at ACR Convergence 2023.
VIDEO: Rheumatology ‘lagging behind’ in precision medicine; gout guidelines still divisive
In a Healio video exclusive, Leonard Calabrese, DO, chief medical editor of Healio Rheumatology, offered a breakdown of the October issue, including the cover story which delved into the topic of individualized precision medicine.
Lessons for diagnosing, managing acute joint pain
A 70-year-old Korean-born man calls in on Monday morning to make an appointment for an evaluation of acute joint pain, which started yesterday. He is in a significant amount of pain and would like to be seen today if possible.
Adding methotrexate to pegloticase for gout increases response rate through 52 weeks
Patients who receive pegloticase alongside methotrexate for gout demonstrate higher response rates and fewer discontinuations, and were more likely to achieve tophi resolution, vs. those treated with pegloticase alone, according to data.
FDA approves Ilaris for the treatment of gout flares in adults
The FDA has approved Ilaris for the treatment of gout flares in adults, marking it as the first biologic therapy to receive the nod for this indication, according to a statement from Novartis.
Gout clinical practice guidelines disagree on when to start urate lowering therapy
Clinical practice guidelines for gout disagree on when urate lowering therapy should begin and how long it should last, as well as on the use of vitamin C, pegloticase, fenofibrate and losartan, according to data published in BMC Rheumatology.
Women’s risk for gout doubles after menopause
Post-menopausal women demonstrate a risk for gout that is two times that of women who have not yet reached menopause, according to a presenter at the 2023 AWIR annual conference.
FDA grants competitive generic therapy approval for indomethacin suppositories
The FDA has granted final approval to Zydus Lifesciences to manufacture and market generic indomethacin 50 mg suppositories, according to a company press release.
Rapid crystalline arthritis treatment requires recognition of various disease types
AUSTIN, Texas — Although gout is the most common, the ability to recognize, diagnose and treat other types of crystalline arthritis can make all the difference for patients, noted a speaker at the 2023 Rheumatology Nurses Society conference.
SGLT2 inhibitors may reduce recurrent gout flares in patients with type 2 diabetes
SGLT2 inhibitors were associated with a reduction in recurrent flares and gout-related ED visits among patients with type 2 diabetes and gout, according to research published in Annals of Internal Medicine.